The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Information source: Huashan Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Idiopathic Parkinson's Disease
Intervention: pramipexole (Drug); Sinemet CR (Drug)
Phase: N/A
Status: Completed
Sponsored by: Huashan Hospital Official(s) and/or principal investigator(s): Jian Wang, MD, Principal Investigator, Affiliation: Fudan University
Summary
Levodopa and non-ergot dopaminergic agonists such as pramipexole are both recommended as the
first-line symptomatic treatment for early untreated Parkinson's disease (PD), previous
clinical trial indicated that initial pramipexole owns advantage over levodopa regarding
motor complications, on the contrary, less adverse effect like freezing and severe
somnolence favors initial treatment of levodopa. Thus, it remains controversial that
initiation of which medication will be better for those patients with early PD.
PDRP (Parkinson's disease-related spatial covariance pattern) is a new biomarker which can
represent the network activity of brain and severity of PD. Based on the literatures and our
previous data, the investigators hypothesize that PDRP will be served as a biomarker to help
us evaluate and compare the effect of levodopa or pramipexole on the progression of PD,
which might be able to provide further evidence for clinicians to address the above critical
issue.
Clinical Details
Official title: a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Longitudinal change of brain network activity evaluated by Parkinson's disease-related spatial covariance pattern(PDRP) value(Z score)
Secondary outcome: Unified Parkinson's Disease Rating Score (II, III, and total)Parkinson's Disease Questionnaire (PDQ39) Hoehn&Yahr staging clinical global impression scale
Detailed description:
CALM-PD study found that Pramipexole can reduce the occurrence of motor complication
compared with Levodopa used as initiative treatment, but it still remains debatable that
initiation of which medication will be better for those patients with De Novo PD.
PDRP (Parkinson's disease-related spatial covariance pattern) is a biomarker which can
represent the network activity of cortico-striato-pallido-thalamocortical pathways and
highly reproducible with stable network activity in individual subjects. The study published
in "J Neuroscience" in 2010 showed that the abnormal PDRP antecede the appearance of motor
signs by about 2 years, indicating PDRP might be a very promising biomarker for identifying
PD at its early stage. Moreover, PDRP is able to represent the progression and severity of
PD as well. It was reported that Levodopa can reduce the PD-related network activity, and
the degree of network suppression correlates with the clinical improvement. However, there
is no study currently showing the impact of pramipexole on brain PDRP network compared with
levodopa as initiative treatment.
Eligibility
Minimum age: 30 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- idiopathic Parkinson's disease meeting UK brain bank criteria
- De Novo
- Hoehn&Yahr staging I-II
Exclusion Criteria:
- Atypical Parkinsonism
- Pregnant or breast-feeding women
- those with abnormal Liver/kidney function
- those participating other clinical trials within 30 days before being enrolled for
this trial.
Locations and Contacts
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai 200040, China
Additional Information
Related publications: Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol. 2007 Feb 28;557(2-3):132-40. Epub 2006 Nov 14. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005 Feb;62(2):241-8. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson's disease. Brain. 2007 Jul;130(Pt 7):1834-46. Epub 2007 Apr 30. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab. 2007 Mar;27(3):597-605. Epub 2006 Jun 28. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci. 2010 Jan 20;30(3):1049-56. doi: 10.1523/JNEUROSCI.4188-09.2010. Wang J, Ma Y, Huang Z, Sun B, Guan Y, Zuo C. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. J Neurol. 2010 Jan;257(1):72-8. doi: 10.1007/s00415-009-5267-3. Epub 2009 Aug 7.
Starting date: December 2011
Last updated: August 23, 2014
|